DCAF5 Gene Test (DDB1 And CUL4 Associated Factor 5)

• Identify whether you carry variants in DCAF5, a WD repeat substrate receptor that forms part of the CRL4--DCAF5 ubiquitin ligase complex and directs the ubiquitination of methylated non histone proteins such as SOX2, DNMT1, and E2F1.
• Help explain, in specialised oncology contexts, why certain SMARCB1 deficient cancers or renal clear cell carcinomas may behave differently or respond differently to targeted therapies or immunotherapy when DCAF5 expression and activity are altered.
• Add context to epigenetic and transcriptional regulation, since DCAF5 influences the stability of proteins that maintain DNA methylation patterns and regulate developmental and differentiation programs, with consequences for tumour progression and possibly for tissue specific gene expression.
• Inform future facing, research aligned discussions around targeted therapies, including the concept that pharmacological inhibition of DCAF5 can restore SWI/SNF tumour suppressor function in SMARCB1 mutant cancers and modulate immune checkpoint gene expression.
• Clarify your baseline ubiquitin mediated quality control architecture within chromatin and transcriptional regulation pathways, so longer term cancer prevention and treatment planning can increasingly integrate this information alongside standard clinical markers as evidence matures.

DCAF5 (DDB1 and CUL4 associated factor 5) is a protein coding gene located on chromosome 14q24.1 that encodes a WD repeat containing protein serving as a substrate receptor for the CUL4--DDB1 E3 ubiquitin ligase complex (CRL4--DCAF5).

As a member of the DCAF family, DCAF5 binds to the adaptor protein DDB1 and recruits specific methylated non histone substrates to the CUL4--RING ligase core for K48 linked polyubiquitination and proteasomal degradation. Known substrates include the transcription factor SOX2, the maintenance DNA methyltransferase DNMT1, and the cell cycle regulator E2F1, positioning DCAF5 as a post translational regulator of stemness, epigenetic maintenance, and proliferation.

As part of CRL4--DCAF5, DCAF5 recognises methylated motifs on target proteins and brings them into proximity with the CUL4--RING ligase machinery, which attaches ubiquitin chains that label the proteins for destruction by the proteasome. This controlled degradation helps maintain appropriate levels of transcription factors, DNA methylation maintenance enzymes, and cell cycle regulators.

In SMARCB1 deficient cancers, DCAF5 has been shown to act as a quality control factor that targets incomplete or mutant SWI/SNF chromatin remodeling complexes (BAF and PBAF) for degradation, thereby silencing SWI/SNF mediated tumour suppressive gene expression programmes. Genetic or pharmacologic inhibition of DCAF5 in these contexts allows residual SWI/SNF complexes to re accumulate at target loci, restore differentiation associated transcriptional programmes, and reverse malignant phenotypes in vitro and in vivo.

More broadly, DCAF5 expression and genetic alterations correlate with immune cell infiltration patterns, immune checkpoint gene expression, and prognosis across multiple cancer types, suggesting that DCAF5 also influences tumour immune microenvironment and response to immunotherapy.

DCAF5 contributes to interconnected domains of protein quality control, epigenetic stability, and cancer biology. By controlling the turnover of methylated SOX2, DNMT1, E2F1, and mutant SWI/SNF complexes, DCAF5 shapes stemness, DNA methylation signatures, cell cycle progression, and differentiation status.

Pan cancer analyses have identified DCAF5 as an emerging prognostic biomarker with context dependent dual roles: in some tumours, higher DCAF5 expression associates with worse outcomes and sustains oncogenic programmes, while in others such as renal clear cell carcinoma, DCAF5 is downregulated and lower expression correlates with more advanced grade, suggesting a possible tumour suppressor role via stabilisation of non SWI/SNF tumour suppressors or modulation of immune checkpoints.

For immuno oncology, DCAF5 expression relates to immune infiltration scores and RNA modification and immune checkpoint genes, and has shown predictive value for immunotherapy outcomes comparable to or exceeding several established markers such as tumour mutational burden and T cell clonality in some cohorts. This positions DCAF5 as a candidate biomarker for immunotherapy stratification and a potential drug target in SMARCB1 mutant and other DCAF5 dependent cancers.

It is easy to assume that DCAF5 testing and standard oncological markers tell you the same story, but they capture different layers of your biology. Imaging, histology, and classical tumour markers describe tumour burden and behaviour now; sequencing of driver genes such as SMARCB1, TP53, or VHL reveals primary oncogenic lesions; DCAF5 status provides insight into the quality control machinery that governs turnover of key chromatin, stemness, and methylation regulators and shapes how flexible tumour states are.

This distinction matters because two cancers with similar driver mutations may behave differently if one depends on DCAF5 to maintain its malignant transcriptional state and is vulnerable to DCAF5 inhibition, while the other does not. DCAF5 also complements, rather than replaces, epigenetic and immune markers by adding a post translational regulatory layer that influences gene expression and immune microenvironment indirectly through substrate stability.

The influence of DCAF5 variants is shaped more by tumour context, coexisting driver mutations, and treatment landscape than by the gene alone. Several factors can alter how DCAF5 biology translates into real world outcomes.

• Driver mutations and chromatin context: The presence of SMARCB1 loss of function, specific SWI/SNF complex alterations, or other chromatin remodeling defects makes tumours more likely to depend on DCAF5 mediated degradation of mutant SWI/SNF complexes and therefore more vulnerable to DCAF5 targeting.
• Epigenetic landscape and DNA methylation: Since DCAF5 regulates DNMT1 and other methylated substrates, the baseline DNA methylation pattern, PRC2 activity, and H3K27 trimethylation levels will influence the impact of DCAF5 perturbation on differentiation and tumour suppressor programmes.
• Immune microenvironment: The density and composition of immune infiltrates, baseline immune checkpoint expression, and pre existing inflammation shape how DCAF5 related changes in immune checkpoint gene expression and RNA modification genes affect immunotherapy responses.
• Treatment exposures: Exposure to DNA damaging agents, epigenetic therapies, or immunotherapy can interact with DCAF5 status by changing the selection pressure on tumour cells that rely on DCAF5 for protein quality control and immune evasion.
• Host factors and co morbidities: Patient specific factors such as organ function, comorbid autoimmune disease, and background immune competence influence how DCAF5 associated pathways translate into prognosis and treatment tolerance.

Yes. In the germline, many individuals with DCAF5 variants or copy number changes may never develop a recognisable DCAF5 related syndrome, and current evidence does not define a clear inherited DCAF5 disease in the general population. Most of the functional and prognostic data relate to somatic alterations, expression changes, or DCAF5 dependency in tumour cells.

Even within cancers, some tumours show DCAF5 alterations without a clear impact on outcome, because other pathways dominate their biology. Conversely, tumours without obvious DCAF5 mutations can be strongly dependent on DCAF5 protein function due to synthetic lethal interactions, such as those seen in SMARCB1 deficient malignancies, which only become apparent in functional screens rather than routine sequencing.

Common DCAF5 genotypes mainly differ at expression and copy number levels rather than well characterised single nucleotide changes with known functional consequences. From a practical perspective, differences in DCAF5 status are often defined by expression, amplification, or loss in tumours.

• Reference / typical DCAF5 status: Germline pattern with no known high impact alterations, where DCAF5 functions as part of general protein quality control and epigenetic maintenance machinery, and cancer risk and behaviour are driven more by other genes and environment.
• DCAF5 amplification or overexpression in tumours: In some cancers, increased DCAF5 expression or gene amplification may support oncogenic programmes by degrading tumour suppressive complexes or stabilising pro tumour substrates, and can correlate with poorer prognosis and potential immunotherapy resistance.
• DCAF5 downregulation or deletion in tumours: In other cancers such as renal clear cell carcinoma, lower DCAF5 expression is associated with higher grade and worse survival, suggesting a possible tumour suppressor role in stabilising key regulators like VHL/p53 axis or restraining immune escape, although mechanisms remain under investigation.

For germline DNA based DCAF5 testing, preparation is straightforward because your genotype does not change over time. The main consideration is whether DCAF5 information will be clinically actionable in your context, which currently is primarily in research or advanced oncology settings.

In tumours, DCAF5 status is typically assessed via sequencing, expression profiling, or immunohistochemistry on biopsy specimens as part of a broader molecular workup. No special preparation beyond standard biopsy and pathology procedures is required, and interpretation should be led by an oncology team familiar with DCAF5's emerging role.

A DCAF5 test is most valuable today in specific oncology and research contexts rather than for general prevention, and decisions should be guided by specialists. It is less useful as a stand alone test outside a clear clinical scenario.

• SMARCB1 deficient cancers or suspected SWI/SNF driven tumours: In these aggressive paediatric and adult cancers, DCAF5 testing may become increasingly relevant as targeted therapies and clinical trials focused on DCAF5 inhibition emerge.
• Renal clear cell carcinoma and selected solid tumours: DCAF5 expression and alteration patterns can add prognostic and immunotherapy response insight when interpreted alongside established markers, and may become part of comprehensive molecular profiling.
• Pan cancer immunotherapy stratification: In research settings and future practice, DCAF5 may complement or refine existing biomarkers such as tumour mutational burden, PD-L1 expression, and immune gene signatures for immunotherapy planning.
• Exploratory precision oncology panels: For patients enrolled in advanced genomic and functional screening programmes, DCAF5 status and dependency can inform eligibility for future trials targeting ubiquitin mediated quality control pathways.